All sponsors

EMD Serono Research & Development Institute, Inc. $MRK.DE

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-35
RECRUITING4
READOUTS ≤12 MONTHS1
Open EMD Serono Research & Development Institute, Inc. on the live radar map → 📅 $MRK.DE readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Tepotinib
NCT02864992
P2Active, not recruitingAdvanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification; Lung Adenocarcinoma Stage IIIB/IV3372022-05-16 (+50 mo)
Avelumab
NCT05327530
P2Active, not recruitingLocally Advanced or Metastatic Urothelial Carcinoma2562025-06-20 (-14 mo)
Avelumab
NCT03815643
P3Active, not recruitingSolid Tumors2052026-11-24 (+34 mo)
M9140
NCT06710132
P1/2Active, not recruitingSolid Tumors; Gastric Cancer1842027-12-23 (-13 mo)
ELOWEN-1
NCT07332481
P3RecruitingSystemic Lupus Erythematosus (SLE); Cutaneous Lupus Erythematosus (CLE)2022029-05-24
Enpatoran
NCT07355218
P3RecruitingSystematic Lupus Erythematosus; Cutaneous Lupus Erythematosus2022029-05-25
Precemtabart tocentecan
NCT07549412
P3RecruitingMetastatic Colorectal Cancer10202029-10-16
Enpatoran
NCT07840287
P3RecruitingSystemic Lupus Erythematosus (SLE); Cutaneous Lupus Erythematosus (CLE)4042031-09-01